Compare ADMA Biologics Inc (ADMA) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs ON Holding AG — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while ON Holding AG trades at $31.31 (market cap $10.33B). The key difference: ON Holding AG is far larger — about 4.7× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| ADMA | ONON | |
|---|---|---|
Market Cap | $2.22B | $10.33B |
Sector | Health | Technology |
52-Week High | $20.38 | $50.63 |
52-Week Low | $7.60 | $30.91 |
Enterprise Value | $2.29B | $9.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
ONON trades at $37.55, up 0.56% with bullish technical signals supported by moving averages. The company demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $0.47 vs. $0.34 expected, maintaining a streak of earnings surprises. Revenue growth to $3.01B in 2025 and expanding net margins to 8.02% reflect operational strength amid positive analyst sentiment.
The outlook remains positive with 77% analyst buy ratings and $52.57 consensus price target suggesting 40% upside potential. Key risks include premium valuation metrics (P/E 41.8, P/S 6.5) and tariff exposure, but strong DTC growth and margin expansion support the bullish case for growth investors seeking athletic footwear exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
